AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) for approval within ... Read More
Bristol Myers Squibb’s Opdivo set for EMA approval in urothelial carcinoma
Bristol Myers Squibb (NYSE: BMY), a global leader in biopharmaceuticals, has reached a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) ... Read More